Solid, sustainable governance

Honesty, ethics and integrity are bedrock values integral to the Grifols culture. The company's behavior – the way we do business – is tied to our commitment to the United Nations Sustainability Development Goals defined in our 2030 agenda. As a business, we embed ethics and sustainability in every decision, integrating human rights (see our Human Rights Policy, the Human Rights Due Diligence Report 2023, and our Modern Slavery & Supply Chain Transparency Statement 2024) and high ethical standards across our operations.

 

Sustainability governance at Grifols is anchored in our corporate structure and strategic decision-making. The Board of Directors, through its dedicated Sustainability, Communication and Reputation Committee, oversees ESG compliance, alignment with corporate values and transparency in both financial and non-financial disclosures. 

Formal responsibilities are assigned across departments, and sustainability performance is regularly monitored, disclosed and independently audited in line with the EU Corporate Sustainability Reporting Directive (CSRD) and other regulatory and voluntary reporting frameworks. This governance model reinforces transparency, accountability and alignment with Grifols’ broader strategic and reputational goals.

 

This strategic focus is reflected in the company’s corporate objectives with 15% directly linked to ESG factors – 25% addressing environmental priorities, 40% focused on social impact and 35% aligned with governance criteria – underscoring the integral role sustainability plays in Grifols’ decision-making and long-term value creation.

Compliance and transparency

Our commitment to doing what is right is reflected  in our Code of Ethics and Code of Conduct. These precepts, together with Crime Prevention and Anti-Corruption policies, form the backbone of Grifols’ global compliance program.

 

We have incorporated more than 15 corporate policies into our daily operations. Each year, we publish a comprehensive review of our financial performance and the integration with environmental, social responsibility and corporate governance criteria, as well as our interactions with healthcare professionals and healthcare and patient advocacy organizations worldwide.

An ethical approach to science and innovation

At Grifols, bioethics guide our research, development, production and marketing practices.

 

We only use plasma from qualified donors, strictly adhering to all relevant regulations in the production of plasma-derived therapies.

 

When pricing our treatments, we follow two core principles. First, cost should never get in the way of patients receiving optimal care and treatment. Second, pricing must support the company's long-term sustainability and reinforce our commitment to innovation and the development of new therapies.

 

On the other hand, we are committed to protecting the rights, safety and well-being of patients who participate in clinical trials. In this regard, our clinical research follows internationally recognized standards such as ICH GCP and the Declaration of Helsinki, as well as all applicable local regulations. Trials begin only after thorough review and approval by regulatory authorities and independent ethics committees.

Our ethical approach is defined by three universal principles:

  • Respect for people: Ensuring informed, autonomous decision‑making and additional safeguards for vulnerable participants.
  • Welfare: Making participant health the top priority and minimizing risks throughout the research process.
  • Justice: Promoting fairness, equal treatment and the protection of individuals from unjustified or unsafe conditions.

 Through this ethical, transparent and patient-centered approach, Grifols ensures that scientific progress always advances hand in hand with the highest standards of health and safety.

Responsible sourcing

At Grifols we take pride in the rigorous and ethical management of our value chain, consistently exceeding regulatory requirements in quality and sustainability. We foster a responsible and resilient supply chain, integrating due diligence policies and procedures, ESG criteria and open dialogue with our partners. 

 

We continuously implement new procedures, analytical tools, data control systems and supplier management practices to deepen our understanding and enhance oversight of our supply chain, allowing us to stay ahead of ESG risks and evolving regulatory requirements.

 

Our strong commitment to quality and safety in our products and services is embedded across all our operations, helping us build lasting trust with patients, plasma donors, and the healthcare community. 

95% of suppliers by spending (volume)
have been evaluated
under ESG criteria (2025)

Animal welfare

Grifols is committed to the ethical treatment of animals in research, recognizing their intrinsic value and society’s concerns. Our Animal Welfare Policy sets our welfare requirements based on the principle that animals should always be considered as living creatures, ensuring their use for research purposes is limited to areas that ultimately benefit human health. 

 

We believe in responsible science that respects animal welfare. Whenever research involving animals is necessary, we follow a clear ethical approach: we look for alternatives first, use only the number of animals required for reliable results and constantly improve how we care for them. This commitment – known as the 3Rs (Replace, Reduce, Refine) – guides our actions and drives innovation in how we conduct research. 

 

When the use of animals is necessary to support the efficacy, safety or quality of our products or research programs, we apply and often exceed regulatory standards to minimize animal use and enhance welfare. All procedures are subject to strict oversight, and our facilities, staff training and supplier audits reflect our dedication to responsible and humane research practices.

The responsible use of artificial intelligence

To remain a market leader and innovator, Grifols is integrating artificial intelligence (AI) strategically and ethically across the organization. We embrace the power of AI and advanced analytics to shape the next generation of breakthroughs, accelerating the delivery of therapeutics and healthcare solutions to patients while improving efficiency and productivity.

 

In 2024, Grifols introduced its AI manifesto, committing to a human-centered approach that prioritizes ethics, responsible use, sustainability and regulatory compliance in all AI applications. This manifesto guides how we explore and implement AI technologies to ensure they align with our values and serve the best interests of patients and society.

The 10 principles for AI use

Promote understanding and clarity on the full lifecycle of AI systems.

Take ownership for the actions and results of our AI systems, with people accountable for solutions.

Mitigate bias to prevent any type of potential discriminatory outcomes, especially on sensitive data related to individuals.

Comply with all applicable data protection and privacy laws and regulations whilst using AI systems.

Protect against cyberthreats and other security risks affecting AI systems through robust security measures that ensure confidentiality.

Ensure all AI solutions comply with applicable regulations and industry best practices.

Foster collaboration between diverse stakeholders internally and externally.

Put in place monitoring mechanisms of AI systems to identify and mitigate potential legal and ethical risks.

Consider the social and healthcare ecosystem impact of AI, improving patient quality of life in line with our sustainability principles.

Foster awareness and provide ongoing education to build a strong, responsible AI culture.

Leading with ethics

Sustainability

Our commitment to sustainability

Grifols' longstanding commitment to people and the planet entails helping society on all fronts by strengthening our positive social, economic and environmental impacts.